Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sweta Rani

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
International Journal of Cancer|May 28, 2011
MAGE-D4B is a novel marker of poor prognosis and potential therapeutic target involved in breast cancer tumorigenesisSerena Germano, Susan Kennedy, Sweta Rani, et al.
Cancer Biology & Therapy|June 14, 2013
Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell linesAisling Pierce, Patricia M McGowan, Maura Cotter, et al.
Pharmaceutics|July 2, 2021
Dexamethasone-Loaded Nanostructured Lipid Carriers for the Treatment of Dry Eye DiseaseSangeeta Kumari, Madhuri Dandamudi, Sweta Rani, et al.
European Journal of Cancer (Oxford, England : 1990)|March 5, 2013
Exosomes from triple-negative breast cancer cells can transfer phenotypic traits representing their cells of origin to secondary cellsKeith O'Brien, Sweta Rani, Claire Corcoran, et al.
Proteomics|May 25, 2012
The use of LC-MS to identify differentially expressed proteins in docetaxel-resistant prostate cancer cell linesKathleen O'Connell, Maria Prencipe, Amanda O'Neill, et al.
Plos One|December 20, 2012
Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomesClaire Corcoran, Sweta Rani, Keith O'Brien, et al.
Oncotarget|September 30, 2015
miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivityKeith O'Brien, Michelle C Lowry, Claire Corcoran, et al.
Cancer Research|May 31, 2014
Neuromedin U: a candidate biomarker and therapeutic target to predict and overcome resistance to HER-tyrosine kinase inhibitorsSweta Rani, Claire Corcoran, Liam Shiels, et al.
Molecular Cancer|October 11, 2011
Characterisation and manipulation of docetaxel resistant prostate cancer cell linesAmanda J O'Neill, Maria Prencipe, Catherine Dowling, et al.
BMC Cancer|October 12, 2018
Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAILAlex J Eustace, Neil T Conlon, Martina S J McDermott, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
International Journal of Cancer|May 28, 2011
MAGE-D4B is a novel marker of poor prognosis and potential therapeutic target involved in breast cancer tumorigenesisSerena Germano, Susan Kennedy, Sweta Rani, et al.
Cancer Biology & Therapy|June 14, 2013
Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell linesAisling Pierce, Patricia M McGowan, Maura Cotter, et al.
Pharmaceutics|July 2, 2021
Dexamethasone-Loaded Nanostructured Lipid Carriers for the Treatment of Dry Eye DiseaseSangeeta Kumari, Madhuri Dandamudi, Sweta Rani, et al.
European Journal of Cancer (Oxford, England : 1990)|March 5, 2013
Exosomes from triple-negative breast cancer cells can transfer phenotypic traits representing their cells of origin to secondary cellsKeith O'Brien, Sweta Rani, Claire Corcoran, et al.
Proteomics|May 25, 2012
The use of LC-MS to identify differentially expressed proteins in docetaxel-resistant prostate cancer cell linesKathleen O'Connell, Maria Prencipe, Amanda O'Neill, et al.
Plos One|December 20, 2012
Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomesClaire Corcoran, Sweta Rani, Keith O'Brien, et al.
Oncotarget|September 30, 2015
miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivityKeith O'Brien, Michelle C Lowry, Claire Corcoran, et al.
Cancer Research|May 31, 2014
Neuromedin U: a candidate biomarker and therapeutic target to predict and overcome resistance to HER-tyrosine kinase inhibitorsSweta Rani, Claire Corcoran, Liam Shiels, et al.
Molecular Cancer|October 11, 2011
Characterisation and manipulation of docetaxel resistant prostate cancer cell linesAmanda J O'Neill, Maria Prencipe, Catherine Dowling, et al.
BMC Cancer|October 12, 2018
Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAILAlex J Eustace, Neil T Conlon, Martina S J McDermott, et al.
Pageof 5